LOWER: Lomitapide Observational Worldwide Evaluation Registry
Phase of Trial: Phase IV
Latest Information Update: 14 Nov 2018
Price : $35 *
At a glance
- Drugs Lomitapide (Primary)
- Indications Hyperlipoproteinaemia type IIa
- Focus Adverse reactions
- Acronyms LOWER
- Sponsors Aegerion Pharmaceuticals
- 14 Nov 2018 Results of analysis using a published model of life expectancy and time to first MACE, presented at the 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
- 14 Apr 2018 Results (n= 163; data cut off; 1 march 2017) of long-term liver safety of lomitapide at three year presented at The International Liver Congress 2018.
- 12 Mar 2018 Results (n=163) assessing 3 years of data of lomitapide in patients with homozygous familial hypercholesterolemia, were presented at the 67th Annual Scientific Session of the American College of Cardiology.